Phase I clinical trial of gemcitabine (GEM) in combination with PF-00477736 (PF-736), a selective inhibitor of CHK1 kinase.

3062 Background: The S-phase and G2-checkpoints are critical mediators of the cell cycle response to cytotoxic therapy. PF-736 is a selective inhibitor of the S/G2-checkpoint kinase CHK1, displayin...